iPS cells from diabetic patients

从线粒体DNA A3243 G突变的患者中成功地获得了iPS细胞（Mt-iPS细胞），Mt-iPS细胞表现出双峰突变异质性。14个克隆中有6个的突变频率降低到检测不到的水平，而其他克隆的突变频率与原始成纤维细胞中的突变频率相比增加了数倍。在连续细胞培养传代期间和分化后，未观察到突变复发或异质性水平无显著变化。突变丰富，稳定的Mt-iPS细胞可能是体外人类线粒体疾病建模的合适细胞来源。无突变的iPS细胞可以为自体移植治疗提供无限制的、无疾病的细胞供应。

iPS cells were successfully generated from patients with the mtDNA A3243G mutation(Mt-iPS).The Mt-iPS cells exhibited a bimodal degree of mutation heteroplasmy. The mutation frequencies decreased to an undetectable level in six of 14 clones, while the others showed several-fold increases in mutation frequencies compared with those in the original fibroblasts. During serial cell culture passage and after differentiation, no recurrence of the mutation or no significant changes in the levels of heteroplasmy were seen. Mutation-rich, stable Mt-iPS cells may be a suitable source of cell for human mitochondrial disease modelling in vitro. Mutation-free iPS cells could provide an unlimited, disease free supply of cells for autologous transplantation therapy.